{"name":"SK Bioscience Co., Ltd.","slug":"sk-bioscience-co-ltd","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":5,"colorKey":"immunology","drugs":[{"name":"GBP560-B","genericName":"GBP560-B","slug":"gbp560-b","indication":"Other","status":"phase_1"},{"name":"IMOJEV","genericName":"IMOJEV","slug":"imojev","indication":"Prevention of Japanese encephalitis in endemic regions","status":"phase_3"},{"name":"IXIARO","genericName":"IXIARO","slug":"ixiaro","indication":"Other","status":"marketed"},{"name":"NBP608 (Low Potency)","genericName":"NBP608 (Low Potency)","slug":"nbp608-low-potency","indication":"Other","status":"phase_3"},{"name":"SKYVaricella®","genericName":"SKYVaricella®","slug":"skyvaricella","indication":"Prevention of varicella (chickenpox) in children and adults","status":"marketed"}]},{"name":"Infectious Disease","slug":"infectious-disease","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"GBP510 adjuvanted with AS03","genericName":"GBP510 adjuvanted with AS03","slug":"gbp510-adjuvanted-with-as03","indication":"Respiratory syncytial virus (RSV) infection in older adults (most likely indication based on SK Bioscience pipeline)","status":"phase_3"}]},{"name":"Immunology","slug":"immunology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"cardiovascular","drugs":[{"name":"NBP608 (Mid Potency)","genericName":"NBP608 (Mid Potency)","slug":"nbp608-mid-potency","indication":"Inflammatory skin conditions (dermatitis, eczema, psoriasis)","status":"phase_3"}]}],"pipeline":[{"name":"GBP510 adjuvanted with AS03","genericName":"GBP510 adjuvanted with AS03","slug":"gbp510-adjuvanted-with-as03","phase":"phase_3","mechanism":"GBP510 is a recombinant protein subunit vaccine designed to stimulate immune responses against a specific pathogen or disease target, formulated with AS03 adjuvant to enhance immunogenicity.","indications":["Respiratory syncytial virus (RSV) infection in older adults (most likely indication based on SK Bioscience pipeline)"],"catalyst":""},{"name":"GBP560-B","genericName":"GBP560-B","slug":"gbp560-b","phase":"phase_1","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"IMOJEV","genericName":"IMOJEV","slug":"imojev","phase":"phase_3","mechanism":"IMOJEV is a live attenuated Japanese encephalitis virus vaccine that stimulates immune responses to prevent Japanese encephalitis infection.","indications":["Prevention of Japanese encephalitis in endemic regions"],"catalyst":""},{"name":"IXIARO","genericName":"IXIARO","slug":"ixiaro","phase":"marketed","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"NBP608 (Low Potency)","genericName":"NBP608 (Low Potency)","slug":"nbp608-low-potency","phase":"phase_3","mechanism":"NBP608 is a low-potency compound developed by SK Bioscience with an undisclosed mechanism of action currently in phase 3 clinical development.","indications":[],"catalyst":""},{"name":"NBP608 (Mid Potency)","genericName":"NBP608 (Mid Potency)","slug":"nbp608-mid-potency","phase":"phase_3","mechanism":"NBP608 is a mid-potency corticosteroid that reduces inflammation by binding to glucocorticoid receptors and suppressing immune and inflammatory responses.","indications":["Inflammatory skin conditions (dermatitis, eczema, psoriasis)","Allergic and inflammatory disorders"],"catalyst":""},{"name":"SKYVaricella®","genericName":"SKYVaricella®","slug":"skyvaricella","phase":"marketed","mechanism":"SKYVaricella® is a live attenuated varicella-zoster virus vaccine that stimulates immune responses to prevent chickenpox infection.","indications":["Prevention of varicella (chickenpox) in children and adults"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMivwFBVV95cUxNNERPakN4Vk9XdkZ4bWRBd09WOHlvZlRTRDZwVEtIMTcwSGZQdUMzT0kxSjZGdTRhazNDd1NVS19GTVRYd2lFWE1ZYTNkR2dNQzhTSkwwdkRvcXBmcll4M2pwNlBaa3dKLXhCaE1jVGVzSVJJcUNrNHI1aU82MjhOWGswR3FJdV9IZUpqaUJmRGNjUTZVc2hZeHJ5UjRFLThCS2FrZmNDMnJNUV9VeTJxWTIxblczLXFxdDZJX3VFZw?oc=5","date":"2026-04-02","type":"pipeline","source":"AD HOC NEWS","summary":"SK Bioscience Co Ltd Stock: A Key Player in South Korea's Vaccine and Biologics Sector for North Ame - AD HOC NEWS","headline":"SK Bioscience Co Ltd Stock: A Key Player in South Korea's Vaccine and Biologics Sector for North Ame","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiugFBVV95cUxQWUdwZkNJemtUaVFZSW9CcXo4cFFFTFpWbEJabVk0aHFaTVk3MHluMmVqQ0J6UWstZEpzTnNRSEZJdzQ3MUhfM2dEVXFfSjFydzI2Q2tDMTV4dG84cWRMQWtYMDd1UXZRUE5IVjdieXh2eWp0TVFIcGRjVjRkMTBCaEVUTGNqQmktcnR0d2NvdURzQkZaZU1pTWlGVjBvam5nOVR3NVpMUUpZS0dRVDNaNDZzQ0M3bEFKMGc?oc=5","date":"2026-03-28","type":"pipeline","source":"AD HOC NEWS","summary":"SK Bioscience Co Ltd Stock: A Key Player in South Korea's Vaccine Innovation for Global Biotech Inve - AD HOC NEWS","headline":"SK Bioscience Co Ltd Stock: A Key Player in South Korea's Vaccine Innovation for Global Biotech Inve","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwwFBVV95cUxQRUtlZEZpNWR5MlpQNEdHWlBDNk5EM0w2eGJqTUstVXhrR0J5dDJJR0lGbW56d1BhTjJpSUsxY1Q3REc0THRuaTl5Y1RlTUlFUGhwdkxWMDB0SjZWanR5V2hYRVRtUkxoRFh6UUp1cmE2Qld0X1N2NXRuM0xVRVNCUDdIaXhaQUl6c05IQkRpaGZmUUVtdUZVSjViM29QTDJhLVJ1aVR0eGthR0xxRUpFXzVINDhIcmdfb2FuWnJVcEhNZDA?oc=5","date":"2026-03-14","type":"pipeline","source":"AD HOC NEWS","summary":"SK Bioscience Navigates Vaccine Market Headwinds Amid Recovery Strategy - AD HOC NEWS","headline":"SK Bioscience Navigates Vaccine Market Headwinds Amid Recovery Strategy","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizAFBVV95cUxQcTBCSFdZeUQxcXJhZURVV1Qxb0FJOGV0cVpCNENCZnBmMG5SbThBX1hqSFl3NGloQ3BmNm85US1wU1ktLTA2aUIxQkJIUWdjNWFyYmNLTEI0R2VUTXVMbHN6MVBBaERWOUVzVUxrZ0FBLWZncC1GUEFxZ29KLTJaNVpsX2l1ajUzdl9McjZBQVBjRlRyNG04S0N4amktYUJRVVhLUTNnRFZnUkdJQWNHYlJ4cXhIVmJkb3hfTXZQWENuVDRKeUZTRGwxUzU?oc=5","date":"2026-02-03","type":"deal","source":"BioSpace","summary":"SK bioscience In-Licenses RSV Preventive mAb Candidate from Gates Medical Research Institute - BioSpace","headline":"SK bioscience In-Licenses RSV Preventive mAb Candidate from Gates Medical Research Institute","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiygFBVV95cUxPWlRCLVZKMWN0SDVEb3NnZWVDMEtXTEtiNG5Ua29BdWw3ZnVwcVhRb0Y0VHRFV1pscVJPVjlXa2NkdjlHRGhRaTI3YTY2TWdKeGpFMmFIYkVDN00yS2d1MkhaUVk0MEw3QjRDYTB0X1Rfb1h4dkYxcUpPNi1vNjJiTmUzS25raUJpeE9RMXp6S2ZmZjRwSG1LRjBDby1Cb25ORXFORDVUUl80VERqbGtCSWpUYVI3ZzE4SDV6OTNqclZpZ1hVNkNxWU9n?oc=5","date":"2026-01-23","type":"pipeline","source":"Contract Pharma","summary":"SK Bioscience to Support CEPI-Backed Development of Updated Zaire Ebolavirus Vaccine - Contract Pharma","headline":"SK Bioscience to Support CEPI-Backed Development of Updated Zaire Ebolavirus Vaccine","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitAFBVV95cUxQOGRJWW8yNWdRMGU5QjFLTXJJUVdZTzY5ZG5IeGN3N3M4RGNHV09COTVDN29jclBGMW9nZUh0aGc4dnQ3VUp5MnF2OTFpX2tEX0tCSjNoa3NnVld3WXhVekFjN2dSSlVIU3FVS0stcVgwaFRyVmN0M1VOdXlna3V0Nzd0QlZ5a2gwd3J1Sm9EamM2Q1NSM01VQm4zNFRyLWMySTI2b0ZSaHlLdld4X05PR01xQkg?oc=5","date":"2026-01-22","type":"deal","source":"Fierce Pharma","summary":"CEPI bankrolls $30M Ebola vaccine collaboration with Merck, SK Bioscience and others - Fierce Pharma","headline":"CEPI bankrolls $30M Ebola vaccine collaboration with Merck, SK Bioscience and others","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivAFBVV95cUxOV3dtMmRnNk5QbmhtY2RHVVJQQVF6dUNJbWp4Y3l0SS1WR3dvSnNpVDUxa2RHbUh4aUxzQ3E3NTJaMHdLakVIcUN2TFJSczhraWlzOWpZVkhxTkk2d1BNY3JWMXlfakVsbk9yd1UzUmVzN3lFZWVMbnZ1OGlheHd2XzhNQUdDM0FHMTRZWUZXcERNSmhwQVhOZ3lpODh3MXZ3aDlrMFpaTm4wREVPbmJfTGJIY0NLQnNnTE9ZUg?oc=5","date":"2026-01-22","type":"pipeline","source":"The Pharma Letter","summary":"SK bioscience advancing Zaire ebolavirus vaccine in CEPI and Merck & Co collab - The Pharma Letter","headline":"SK bioscience advancing Zaire ebolavirus vaccine in CEPI and Merck & Co collab","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTE1GZndQRzlfckZKbXBEekkxdFM0dmhYWURmQm9nUmFGdk42Y2tHX244b19GNkFmNDdOODdLY3BKVVFUU0MtdWM0X2x1Y2RZNWRNMGMydUE2UzJTNHhkVUhHVG1WNlYzTFFMRFZyeDZ30gFyQVVfeXFMT1FLOTctb0YwQ1VKQTdZSGp6TkUtcU9BT3BVRzJVVzRRNXF6YXBkSUNiVFJJNWZKenhiRktoa3M3VWdHSl9qZUlLcjhmTDB5UFF3dFplbVZhMkw2OTBlT2R1YUlqa1hNdzhpWE4xOS11eU9R?oc=5","date":"2025-01-23","type":"deal","source":"koreabiomed.com","summary":"SK bioscience, Sanofi expand partnership to strengthen vaccine cooperation in Korea - koreabiomed.com","headline":"SK bioscience, Sanofi expand partnership to strengthen vaccine cooperation in Korea","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimwFBVV95cUxORE1PRnNrcjY3ZUdOTWRnVExDWXRybENhSmVhM1RsdjYtTWJIQkdIejZMUG5IZEZfenFFYW5rTWNlbWVtV1JZcDhyZ2k2ZEtyU0xfR3p5MUhzbjBqT09hcTUxWWRmbkhmQXRBQlF4VHVpMWJjVGRLYTE3MHlQd2lXMW1ndEdZcjJJaTVVSEdDY2J3NXVZWEh3V2RWdw?oc=5","date":"2024-12-23","type":"deal","source":"European Biotechnology Magazine","summary":"Sanofi expands collaboration with SK Bioscience - European Biotechnology Magazine","headline":"Sanofi expands collaboration with SK Bioscience","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi0AFBVV95cUxQWklNdml3dmJpUGZkWklEcWhkdXdXaGtQY25kN2VKSkpMOXd1XzdjbEJMWF9waFd5N3cyZEQ1M055X1pCZVY1MmktNzdVSjFNTG5NSkdNZmZPbFJacEhnNG1ZeDF2aFRvVjhuU2ZDcTZCdlB2ZjJtbU1RRm5LQWRMWlUtTlpSbHZrVVJtRWg3Y1FEdzQ5STNhRGNaUkg5eUZTR3I4SWJzS0UyUmJnOWdQblVwNlk2SGFHQWZBZmtMSWs1U2RPUEQ2TGhnU1JzeVJQ?oc=5","date":"2024-10-02","type":"pipeline","source":"prnewswire.com","summary":"South Korea's SK bioscience Completes Acquisition of Germany's CDMO IDT Biologika - prnewswire.com","headline":"South Korea's SK bioscience Completes Acquisition of Germany's CDMO IDT Biologika","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTE5Fd0NaNGdKekR3YU53V2lraFF3R043N2ZLdmlIR0g0ZTc2anpoTEo3bkd6V2RVRHl6Q0hGdWZTR1ZXa01jeDdnSXpnWGVPRFY5bl9ycm1sc3Zqc1ZsTzJTMlJ2YU94dk5kMVhCYmVR?oc=5","date":"2024-08-16","type":"pipeline","source":"KED Global","summary":"SK Bioscience sells stake in US vaccine developer Novavax - KED Global","headline":"SK Bioscience sells stake in US vaccine developer Novavax","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTE9Xd2d2VU1iTTI3SGljR0tNTVVaT0ZqVGxzOWFQd29va1dxSGt1VzNHS3EwXzdrRlM4Tks3NkVsRnZ4dWZhNjNGaXNnaXJOZF9lN2pZVHpjS044NnU5VGEtWnhIT3hHWVA5a0d4UV9B?oc=5","date":"2023-05-08","type":"pipeline","source":"KED Global","summary":"SK Bioscience to produce MSD’s new Ebola vaccine candidate - KED Global","headline":"SK Bioscience to produce MSD’s new Ebola vaccine candidate","sentiment":"neutral"}],"patents":[],"drugCount":7,"phaseCounts":{"phase_3":4,"phase_1":1,"marketed":2},"enrichmentLevel":0,"visitCount":3,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}